Core Insights - Exact Sciences Corporation (EXAS) is focused on promoting Cologuard as the standard of care while advancing digital infrastructure and diagnostics for comprehensive cancer care insights [1] - The company has experienced a stock decline of 17.9% over the past year, contrasting with a 26.9% gain in the S&P 500 Composite [2] - Exact Sciences has a market capitalization of 10.70billionandalong−termearningsgrowthrateof30.61.20 per share, with a projected revenue increase of 9.7% year-over-year to $2.74 billion [13]